TPWA
ACAD icon

Twin Peaks Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-177
Closed -$3.94K – 244
2026
Q1 		$3.94K Buy
+177
New +$4.23K ﹤0.01% 1477
2025
Q3 		– Sell
-318
Closed -$8.09K – 180
2025
Q2 		$8.09K Buy
+318
New +$5.91K ﹤0.01% 1049

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Twin Peaks Wealth Advisors's ACAD Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 177 shares — an estimated $3.94K sold.

Twin Peaks Wealth Advisors first reported a position in ACAD in Q2 2025 and held it in 2 quarters. The position peaked at $8.09K in Q2 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 177 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.94K.
  • Twin Peaks Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Acadia Pharmaceuticals position peaked at $8.09K in Q2 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.